
In the last week, the United States market has stayed flat, yet it is up 30% over the past year with earnings forecast to grow by 16% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often reflect management's confidence in their business prospects and alignment with shareholder interests.
| Name | Insider Ownership | Earnings Growth |
| Uxin (UXIN) | 35.7% | 74.1% |
| Upstart Holdings (UPST) | 12.8% | 53.6% |
| Precigen (PGEN) | 11.9% | 68.4% |
| Karman Holdings (KRMN) | 17% | 53.2% |
| Enovix (ENVX) | 12.4% | 41.1% |
| Clene (CLNN) | 12% | 62.2% |
| Caledonia Mining (CMCL) | 14.3% | 29.6% |
| Better Home & Finance Holding (BETR) | 19.3% | 104% |
| Astera Labs (ALAB) | 10.8% | 27.8% |
| AppLovin (APP) | 27.4% | 22.1% |
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Prenetics Global Limited is a health sciences company that focuses on advancing consumer health in Hong Kong, the United States, and internationally, with a market cap of approximately $308.47 million.
Operations: Prenetics Global Limited generates revenue through its health sciences operations aimed at enhancing consumer health across Hong Kong, the United States, and other international markets.
Insider Ownership: 25.6%
Revenue Growth Forecast: 53.9% p.a.
Prenetics Global is positioned for growth with a forecasted 53.9% annual revenue increase, surpassing the US market average. Despite recent shareholder dilution and volatility in share price, the company trades significantly below its estimated fair value. Prenetics' strategic partnership with Superpower enhances its health offerings, while a $40 million share buyback reflects confidence in future prospects. However, it faces challenges such as limited cash runway and ongoing net losses despite expected profitability within three years.
Simply Wall St Growth Rating: ★★★★★★
Overview: Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.46 billion.
Operations: The company's revenue segment includes Biotechnology (Startups), generating $9.68 million.
Insider Ownership: 11.9%
Revenue Growth Forecast: 39.6% p.a.
Precigen is poised for growth, with revenue expected to increase 39.6% annually, outpacing the US market. Despite a substantial net loss of US$250.64 million in 2025 and recent shareholder dilution, it trades significantly below estimated fair value. Insider activity shows more buying than selling recently, indicating confidence in its future prospects. The company is forecasted to achieve profitability within three years, supported by a high anticipated return on equity of 48.9%.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Diana Shipping Inc. provides shipping transportation services globally with a market cap of $289.33 million.
Operations: The company generates revenue of $213.54 million from its dry-bulk vessels segment.
Insider Ownership: 29.3%
Revenue Growth Forecast: 13.4% p.a.
Diana Shipping shows potential for growth despite a challenging financial position, with earnings expected to grow significantly at 57.6% per year, outpacing the US market. Recent charter agreements are set to bolster revenue, although insider ownership activity is limited. The company trades slightly below its estimated fair value and has an unstable dividend track record. Recent vessel acquisitions and charters indicate strategic expansion, but its return on equity is forecasted to remain low at 11.7%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

All Comments